Mitogenic potency of insulin glargine

Endokrynologia Polska

Volumn 60, Issue 1, 2009, Pages 34-39

  Zełobowska, Katarzyna ^a   Gumprecht, Janusz ^a   Grzeszczak, Władysław ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Glargine; Insulin analogue; Mitogenicity

Indexed keywords

HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN RECEPTOR; SOMATOMEDIN C RECEPTOR;

ATHEROSCLEROTIC PLAQUE; CARCINOGENIC ACTIVITY; DIABETES MELLITUS; DRUG POTENCY; DRUG RECEPTOR BINDING; ENDOTHELIAL DYSFUNCTION; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; INSULIN TREATMENT; MITOGENESIS; MITOGENICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RECEPTOR AFFINITY; RECOMBINANT DNA TECHNOLOGY; REVIEW;

ANIMALS; CELL LINE; DIABETES MELLITUS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MITOGENS; RECEPTOR, IGF TYPE 1;

EID: 64149123460     PISSN: 0423104X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Bliss M. Discovery of insulin. University Of Chicago Press, Chicago 1984.
2. Brange J, Owens DR, Kang S et al. Monomeric insulins and their experimental and clinical implications. Diabetes Care 1990; 13: 923-954.
3. Rosenfeld L. Insulin: discovery and controversy. Clin Chem 2002; 48: 12: 2270-2288.
4. Peterson CM. Symposium on optimal insulin delivery. Introduction: history and goals of insulin treatment. Diabetes Care 1982; 5: 1-5.
5. Gerich JE. Novel insulins: expanding options in diabetes management. Am J Med 2002; 113: 308-316.
6. Brange J, Ribel U, Hansen JF et al. Monomeric insulins obtained by protein engineering and their medical implications. Nature 1988; 333: 679-682.
7. Nakae J, Kido Y, Accili D. Distinct and overlapping functions of insulin and IGF-I receptors. Endocr Rev 2001; 22: 818-835.
8. Lammers R, Gray A, Schlessinger J et al. Differential signaling potential of insulin-and IGF-1-receptor cytoplasmic domains. EMBO J 1989; 8: 1369-1375.
9. Mynarcik DC, Williams PF, Schatter L et al. Identification of common ligand binding determinants of the insulin and insulin-like growth factor 1 receptors. Insights into mechanisms of ligand binding. J Biol Chem 1997; 272: 18650-18655.
10. Slieker LJ, Brooke GS, Dimarchi RD et al. Modifications in the B10 and B26-10 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor. Diabetologia 1997; 40 (suppl. 2): 54-61.
11. Pandini G, Vigneri R, Constantino A et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin//IGF-I hybrid recepto overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5: 1935-1944.
12. Shaw LC, Grant MB. Insulin like growth factor-1 and insulin-like growth factor bindin proteins: their possible roles in both maintaining normal retinal vascular function and in promoting retinal pathology. Rev Endocr Metab Disord 2004; 5: 199-207.
13. Chisalita SI, Arnqvist HJ. Insulin-like growth factor I receptors are more abundant than insulin receptors in human micro-and macrovascular endothelial cells. Am J Physiol Endocrinol Metab 2004; 286: E896-E901.
14. Zib I, Raskin P. Novel insulin analogues and its mitogenic potential. Diab Obes Metab 2006; 8: 611-620.
15. Brange J, Volund A. Insulin analogs with improved pharmacokinetics profiles. Adv Drug Deliv Rev 1999; 35: 307-321.
16. Mc Keage K, Goa KL. Insulin glargine: a review of its therapeutic use as long-acting agent for management of type 1 and 2 diabetes mellitus. Drugs 2001; 61: 1599-1624.
17. Markussen J, Havelund S, Kurzhals P et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1996; 39: 281-288.
18. Heinemann L, Sinha K, Weyer C et al. Time-action profile of the soluble fatty acid acylated, long acting insulin analogue NN304. Diabet Med 1999; 16: 332-338.
19. Bhatnagar S, Srivastava D, Jayadev MS et al. Molecular variants and derivatives of insulin for improved glycemic control in Diabetes. Prog Biophys Mol Biol 2006; 91: 199-228
20. Vincent MT, Carroll RJ, Hammer RE et al. A transgene coding for a human insulin analog has a mitogenic effect on murine embryonic beta cells. Proc Natl Acad Sci USA 1995; 92: 6239-6243.
21. Milazzo G, Sciacca L, Papa V et al. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-1 receptor. Mol Carcinog 1997; 18: 19-25.
22. Kurtzhals P, Schaffer L, Sorensen A et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000; 49: 999-1005.
23. Drejer K, Kruse V, Larsen UD et al. Receptor binding and tyrosine kinase activation by insulin analogues with extreme affinities studied in human hepatoma HepG2 cells. Diabetes 1991; 40: 1488-1495.
24. Bornfeldt KE, Gidleof RA, Wasteson A et al. Binding and biological effects of insulin, insulin analogues and insulin-like growth factors in rat aortic smooth muscle cells. Comparison of maximal growth promoting activities. Diabetologia 1991; 34: 307-313.
25. Drejer K. The bioactivity of insulin analogues from in vitro receptor biding to in vivo glucose uptake. Diabetes Metab Rev 1992; 8: 259-285.
26. Schwartz GP, Burke GT, Katsoyannis PG. A superactive insulin: (B10 - aspartic acid] insulin (human). Proc Natl Acad Aci USA 1987; 84: 6408-6411.
27. Shymko RM, De Meyts P, Thomas R. Logical analysis of timing-dependent receptor signalling specificity: application to the insulin receptor metabolic and mitogenic signalling pathways. Biochem J 1997; 326: 463-469.
28. Berti L, Kellerer M, Bossenmaier B et al. The long acting human insulin analog HOE 901: characteristics of insulin signaling in comparison to Asp(B10) and regular insulin. Horm Metab Res 1998; 30: 123-129.
29. Bolli GB, Owens DR. Insulin Glargine. Lancet 2000; 356: 443-445.
30. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
31. Bolli GB, Di Marchi RD, Park GD et al. Insulin analogues and their potential in management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167.
32. Beahr M, Kolter T, Seipke G et al. Growth promoting and metabolic activity of the human insulin analogue [GlyA21, ArgB31, ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997; 320: 259-265.
33. Ciaraldi TP, Carter I, Seipke G et al. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I J Clin Endocrinol Metab 2001; 86: 5838-5847.
34. Henry RR, Abrams L, Nikoulina S et al. Insulin action and glucose metabolism in non-diabetic control and NIDDM subjects: comparison using human skeletal muscle cell cultures. Diabetes 1995; 44: 935-945.
35. Despres JP, Lamarche B, Mauriege P et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334: 952-957.
36. Yki-Jarvinen H. Insulin resistance and endothelial dysfunction. Best Pract Res Clin Endocrinol Metab 2003; 17: 411-430.
37. Caixas A, Ordonez-Llanos J, de Leiva A et al. Optimization of glycemic control by insulin therapy decreases the proportion of small dense LDL particles in diabetic patients. Diabetes 1997; 46: 1207-1213.
38. Taskinen MR, Kuusi T, Helve E et al. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988; 8: 168-177.
39. Dandona P, Aljada A, Mohanty P. The anti-inflammatory and potential anti-atherogenic effect of insulin: a new paradigm. Diabetologia 2002; 45: 924-930.
40. Gonzales MA, Selwyn AP. Endothelial function, inflammation, and prognosis in cardiovascular disease. Am J Med 2003; 115 (suppl. 1): 99-106.
41. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-175.
42. Banskota NK, Taub R, Zellner K et al. Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-I. Diabetes 1989; 38: 123-129.
43. King GL, Goodman AD, Buzney S et al. Receptors and growth-promoting effects of insulin and insulin-like growth factors on cells from bovine retinal capillaries and aorta. J Clin Invest 1985; 75: 1028-1036.
44. Rossetti P, Pampanelli S, Fanelli C et al. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog At mealtime: a 3-mo comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. Diabetes Care 2003; 26: 1490-1496.
45. Pandini G, Frasca F, Mineo R et al. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277: 39684-39695.
46. Nystrom FH, Ohman PK, Ekman BA et al. Population-based reference values for IGF-I and IGF-binding protein-1: relations with metabolic and anthropometric variables. Eur J Endocrinol 1997; 136: 165-172.
47. Staiger K, Staiger H, Schweitzer MA et al. Insulin and its analogue glargine do not affect the viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 2005; 48: 1898-1905.
48. Fritsche A, Schweitzer MA, Haring HU. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959.
49. Stammberger I, Bube A, Durchfeld-Meyer B et al. Evaluation of the carcinogenic potential of insulin glargine (LANTUS) in rats and mice. Int J Toxico 2002; 21: 171-179.
50. Hofmann T, Horstmann G, Stammberger I. Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int J Toxicol 2002; 21: 181-189.
51. Shymko RM, Dumont E, De Meyts P et al. Timing-dependence of insulin receptor mitogenic versus metabolic signalling: a plausible model based on coincidence of hormone and effector binding. Biochem J 1999; 339: 675-683.
52. Hansen BF, Danielsen GM, Drejer K et al. Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency. Biochem J 1996; 315: 271-279.
53. Ish-Salom D, Christofferson CT, Vorwerk P et al. Mitogenic properties of insulin and insulin analogues mediated by the insulin receptor. Diabetologia 1997; 40 (suppl. 2): 25-31.
54. Rafaeloff R, Yip C, Goldfine I. Binding of mutant insulins to a mutated insulin receptor. Biochem Biophys Res Commun 1992; 188: 318-322.
55. Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 2000; 59: 261-262.
56. Kellerer M, Häring HU. Insulin analogues: impact of cell model characteristics on results and conclusions regarding mitogenic properties. Exp Clin Endocrinol Diabetes 2001; 109: 63-64.